Nigus Dessalew

发表

On the Paradigm Shift Towards Multitarget Selective Drug Design

Nigus Dessalew, Workalemahu Mikre, W. Mikre, 2008 .

Structure-based approaches in the design of GSK-3 selective inhibitors.

Dhilon S. Patel, N. Dessalew, P. Bharatam, 2007, Current protein & peptide science.

Cyclin Dependent Kinase as Significant Target for Cancer Treatment

S. Singh, S. Tripathi, N. Dessalew, 2012 .

Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening.

Prasad V Bharatam, N. Dessalew, P. Bharatam, 2007, Biophysical chemistry.

Structure based de novo design of novel glycogen synthase kinase 3 inhibitors.

N. Dessalew, P. Bharatam, Nigus Dessalew, 2007, Bioorganic & medicinal chemistry.

3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.

S. Singh, N. Dessalew, P. Bharatam, 2007, Medicinal chemistry (Shariqah (United Arab Emirates)).

3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.

N. Dessalew, P. Bharatam, Nigus Dessalew, 2007, European journal of medicinal chemistry.

Investigation of Potential Glycogen Synthase Kinase 3 Inhibitors Using Pharmacophore Mapping and Virtual Screening

N. Dessalew, P. Bharatam, Nigus Dessalew, 2006, Chemical biology & drug design.

3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.

Dhilon S. Patel, N. Dessalew, P. Bharatam, 2007, Journal of molecular graphics & modelling.

QSAR Study on Dual 5‐HT1A and 5‐HT1B Antagonists: An Insight into the Structural Requirement for Antidepressant Activity

N. Dessalew, Nigus Dessalew, 2008, Archiv der Pharmazie.

Multitarget Selective Antidepressants Design: Latest Developments, Opportunities and Challenges

A. Hymete, W. Mikre, Nigus Dessalew, 2008 .

3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.

S. Singh, N. Dessalew, P. Bharatam, 2006, European journal of medicinal chemistry.